Measurement of the pupillary light reflex after critical illness

Recruiting

• Conditions: G62.8; Other specified polyneuropathies

• Registration Number: DRKS00031629
• Lead Sponsor: niversitätsmedizin Göttingen

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-04-05
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Signed informed consent (by participant or legal guardian)

Exclusion Criteria

- acute or chronic severe neurological disease (progressive dementia, degenerative disease of the central nervous system)
- Diseases of the optic system (e.g. glaucoma, macula degeneration, macula degeneration, cerebral infarction of parts of the optic tracts and radiation)
- Current treatment with centrally acting medication with effects on the pupillary light reaction (e.g. opioids and porpofol)
Current treatment with medication directly modifying the pupillary light reaction (medication with mydriatic effects, medication with miotic effects (e.g. parasympathmimetic medication)

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
atency of the pupillary light reflex as measured by an electronic pupillometer (PLR-3000 Pupillometer); once, after the critical phase of the main acute disease

Secondary Outcome Measures

Name	Time	Method
- Amplitude of the pupillary light reflex<br>- Velocity of the pupillary light reflex<br>as measured by an electronic pupillometer each (PLR-3000 Pupillometer)